3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
28
Melanoma
4
Sarcoma
3
Liposarcoma
3
Ovarian Neoplasms
2
Neoplasms
2
Breast Cancer Metastatic
2
Thymus Neoplasms
1
Teratoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neoplastic Cells, Circulating
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma
1
Locoregional Recurrence
1
Liposarcoma, Myxoid
1
Lipoma
1
Leukemia
1
Leiomyosarcoma
1
Hematologic Neoplasms
1
HER2-positive Advanced Breast Cancer
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Interventions
Pemetrexed
10
Cisplatin
9
Gemcitabine
8
Nivolumab
5
Ipilimumab
4
Carboplatin
4
niraparib
3
durvalumab
3
Vinorelbine
3
Bevacizumab
3
tremelimumab
2
pembrolizumab
2
olaparib
2
anetumab ravtansine
2
Radiotherapy, Intensity-Modulated
2
Oxaliplatin
2
Imatinib Mesylate
2
Hyperthermic Intraperitoneal Chemotherapy
2
Fluorodeoxyglucose F18
2
Cytoreduction Surgical Procedures
2
vandetanib
1
tislelizumab
1
tazemetostat
1
spartalizumab
1
sargramostim
1
ribociclib
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
defactinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mesothelioma
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts